Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403541 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Immunovant Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05403541 is a Phase 3 study of Generalized Myasthenia Gravis that is active but no longer recruiting, run by Immunovant Sciences. The registered enrollment target is 240 participants, above the 122-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05403541, a Phase 3 study of Generalized Myasthenia Gravis, is active but no longer recruiting, sponsored by Immunovant Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy will be assessed by change in the MG- ADL score in AChRAb+ participants. Participants demonstrating a response to batoclimab during either Period 1 or 2 may enter the long-term extension (Period 3). Participants who complete Period 3 are eligible to participate in Period 4 (Optional Long-Term extension) according to their treatment assignment in Period 3.
Conditions Studied
Interventions
- DRUG Batoclimab 340 mg SC weekly
- DRUG Batoclimab 680 mg SC weekly
- DRUG Matching Placebo SC
- DRUG Batoclimab 340 mg SC bi-weekly
Study Locations (20)
Florida
- Site Number -1007 - Clearwater
- Site Number -1010 - Maitland
- Site Number - 1020 - Miami
- Site Number - 1019 - Orlando
- Site Number - 1028 - Port Charlotte
- Site Number - 1015 - Tampa
California
- Site Number -1002 - Carlsbad
- Site Number -1009 - Irvine
- Site Number - 1012 - Olive View
- Site Number -1032 - San Francisco
Arizona
- Site Number -1022 - Phoenix
- Site Number -1029 - Scottsdale
Colorado
- Site Number - 1027 - Aurora
Connecticut
- Site Number - 1025 - New Haven
Kansas
- Site Number -1011 - Fairway
Kentucky
- Site Number -1003 - Lexington
Michigan
- Site Number -1013 - East Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403541
The ClinicalTrials.gov registry entry for NCT05403541 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (97% higher). The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 4 interventions - of which Batoclimab 340 mg SC weekly is the first listed.
NCT05403541 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05403541 about?
NCT05403541 is a clinical study titled "Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis". The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint...
What is the current status of trial NCT05403541?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2022-06-27. Estimated completion is 2027-01.
What conditions does trial NCT05403541 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT05403541?
The interventions under investigation include: Batoclimab 340 mg SC weekly (DRUG), Batoclimab 680 mg SC weekly (DRUG), Matching Placebo SC (DRUG), Batoclimab 340 mg SC bi-weekly (DRUG).
Who is sponsoring clinical trial NCT05403541?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403541 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.